Saccharomyces boulardii for the treatment of clostridium difficile- Associated colitis

Annals of Pharmacotherapy

Volumn 31, Issue 7-8, 1997, Pages 919-921

  Eddy, Jeffrey T ^a   Stamatakis, Mary K ^a   Makela, Eugene H ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE; COLON FLORA; FLUID THERAPY; INFECTION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RISK FACTOR; SACCHAROMYCES BOULARDII;

ANTI-BACTERIAL AGENTS; ANTITRICHOMONAL AGENTS; CLINICAL TRIALS, PHASE III; CLOSTRIDIUM DIFFICILE; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; RISK FACTORS; SACCHAROMYCES; VANCOMYCIN; YEAST, DRIED;

EID: 15444351985     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
2. Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 1990;12(suppl 2):S243-51.
3. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269:71-5.
4. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320: 204-10.
5. Stergachis A, Perera DR, Schnell MM, Jick H. Antibiotic-associated colitis. West J Med 1984;140:217-9.
6. Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, part 1. Am J Hosp Pharm 1994;51:1771-81.
7. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678-84.
8. Danziger LH, Itokazu GS. Gastrointestinal infections. In: Young LE, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, Inc., 1995:60-10-12.
9. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwarte MJ. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-6.
10. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.
11. Fekety R, Silva R, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86:15-9.
12. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
13. Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980;78:431-4.
14. Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastrenterol 1989;84:1285-7.
15. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
16. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990;35:897-901.
17. Hassett J, Meyers S, McFarland L, Mulligan ME. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 1995;20(suppl 2):S266-8.
18. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993;16:419-25.
19. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870-6.
20. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269:71-5.
21. Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108-15.
22. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990;35:251-6.
23. Caetano JAM, Parames MT, Babo MJ, Santos A, Bandeira Ferreira A, Freitas AA. Immunopharmacologic effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 1986;8:245-59.
24. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989;10: 353-64.
25. Plentincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5.